Project Grant R00EB012165

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $546,625 to the University of Pittsburgh to develop and evaluate a novel nanoparticle-based immunochemotherapy approach for the treatment of metastatic colorectal cancer (mCRC). The key products and services to be delivered under this 5-year award include: 1) Developing and characterizing a nanocarrier platform (PCL-CP) that can co-deliver small interfering RNA (siRNA)...

This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies,...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $2,304,645 to The Trustees of the University of Pennsylvania to develop and test the efficacy of cardiac-targeted lipid nanoparticles (CLNPs) for the delivery of inhibitory nucleic acids to treat contractile dysfunction in heart failure models. The key research objectives are to: 1) characterize the on- and off-target...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) award of $274,947 to Lattice Therapeutics Inc. supports the development of a customizable, next-generation RNA delivery particle. The project aims to validate the ability of an engineerable protein nanoparticle platform to efficiently and specifically deliver RNA cargoes to target cancer cells. Key objectives include in vitro evaluation of RNA...

This $700,000 Project Grant was awarded on September 20, 2024 by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) to Mirimus, Inc., a small disadvantaged business located in Brooklyn, NY. The funding will support the company's work to create the next generation of RNA interference (RNAi) therapeutics and develop an in vivo model to evaluate their efficacy and biodistribution. Mirimus plans to test several...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $320,251 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Ogb5, Inc. for the development of a non-viral nanoparticle gene therapy delivery platform to treat cystic fibrosis and other chronic lung diseases. The grant aims to further advance Ogb5's proprietary technology, which utilizes DNA and RNA nanoparticles combined with uptake enhancers to improve gene transfer efficiency compared to current viral-based delivery...

Through a $1,000,000 Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program, Optimeos Life Sciences, Inc., a for-profit biotechnology company, is developing a non-viral platform for delivering mRNA-based gene therapies. The project aims to validate a polymer-lipid hybrid formulation that can safely and repeatedly deliver genetic instructions to patients with rare urea cycle disorders, overcoming limitations of current...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to demonstrate the efficacy of using hydrodynamic gene delivery for the treatment of hereditary tyrosinemia type 1 (HT1) and other rare genetic liver diseases. The $881,961 award to Hydrogene Therapeutics Inc. will fund the optimization of a vector system for safe genome integration and...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $594,547 to the University of California, Davis to develop and characterize an orally delivered nanodrug. The nanodrug, named PRORA, is designed to compensate for the shortage of specific microbial metabolite-regulated signaling in liver and colon cancer patients. Preliminary data in...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $1,095,274 to develop complementary biotherapeutic delivery platforms for enabling gene re-delivery. The award, effective August 1, 2024 through May 31, 2029, aims to pioneer innovative delivery strategies that overcome biological barriers and modulate immune responses to improve the effectiveness of adeno-associated virus...